Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:17906695rdf:typepubmed:Citationlld:pubmed
pubmed-article:17906695lifeskim:mentionsumls-concept:C0965644lld:lifeskim
pubmed-article:17906695lifeskim:mentionsumls-concept:C1704632lld:lifeskim
pubmed-article:17906695lifeskim:mentionsumls-concept:C0871261lld:lifeskim
pubmed-article:17906695lifeskim:mentionsumls-concept:C1413430lld:lifeskim
pubmed-article:17906695lifeskim:mentionsumls-concept:C1333897lld:lifeskim
pubmed-article:17906695lifeskim:mentionsumls-concept:C1704838lld:lifeskim
pubmed-article:17906695lifeskim:mentionsumls-concept:C2911692lld:lifeskim
pubmed-article:17906695lifeskim:mentionsumls-concept:C1706817lld:lifeskim
pubmed-article:17906695lifeskim:mentionsumls-concept:C1514526lld:lifeskim
pubmed-article:17906695lifeskim:mentionsumls-concept:C0086597lld:lifeskim
pubmed-article:17906695pubmed:issue13lld:pubmed
pubmed-article:17906695pubmed:dateCreated2008-3-20lld:pubmed
pubmed-article:17906695pubmed:abstractTextHypoxia-inducible factor-1alpha (HIF-1alpha) is destabilized via the ubiquitin-proteasome system. Thus HIF-1alpha expression is robustly upregulated by proteasome inhibition, but paradoxically its activity is reduced. In the present study, we investigated the mechanism underlying the paradoxical response of HIF-1alpha to proteasome inhibition. In both Hep3B and HEK293 cells, a proteasome inhibitor MG132 noticeably attenuated hypoxic induction of erythropoietin and VEGF mRNAs. MG132 inactivated HIF-1alpha C-terminal transactivation domain (CAD), independently of factor inhibiting HIF-1 (FIH) and inhibited p300 recruitment by HIF-1alpha. We next tested the possibility that CITED2 is involved in the HIF-1 inactivation. CITED2 was found to be degraded via the ubiquitin-proteasome system and thus was stabilized by proteasome inhibition. Both the activity and the p300 binding of HIF-1alpha were inhibited by CITED2 expression and recovered by CITED2 siRNA in the presence of MG132. These results suggest that CITED2 is stabilized by proteasome inhibition and inactivates HIF-1 by interfering with the HIF-1alpha-p300 interaction. This may be an important mode-of-action for proteasome inhibition-based cancer therapy.lld:pubmed
pubmed-article:17906695pubmed:languageenglld:pubmed
pubmed-article:17906695pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17906695pubmed:citationSubsetIMlld:pubmed
pubmed-article:17906695pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17906695pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17906695pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17906695pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17906695pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17906695pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17906695pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17906695pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17906695pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17906695pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17906695pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17906695pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17906695pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17906695pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17906695pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17906695pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17906695pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17906695pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17906695pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17906695pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17906695pubmed:statusMEDLINElld:pubmed
pubmed-article:17906695pubmed:monthMarlld:pubmed
pubmed-article:17906695pubmed:issn1476-5594lld:pubmed
pubmed-article:17906695pubmed:authorpubmed-author:ShinD HDHlld:pubmed
pubmed-article:17906695pubmed:authorpubmed-author:LiS HSHlld:pubmed
pubmed-article:17906695pubmed:authorpubmed-author:FeisHHlld:pubmed
pubmed-article:17906695pubmed:authorpubmed-author:PaiR RRRlld:pubmed
pubmed-article:17906695pubmed:authorpubmed-author:HuangL ELElld:pubmed
pubmed-article:17906695pubmed:authorpubmed-author:ParkJ-WJWlld:pubmed
pubmed-article:17906695pubmed:issnTypeElectroniclld:pubmed
pubmed-article:17906695pubmed:day20lld:pubmed
pubmed-article:17906695pubmed:volume27lld:pubmed
pubmed-article:17906695pubmed:ownerNLMlld:pubmed
pubmed-article:17906695pubmed:authorsCompleteYlld:pubmed
pubmed-article:17906695pubmed:pagination1939-44lld:pubmed
pubmed-article:17906695pubmed:dateRevised2011-11-17lld:pubmed
pubmed-article:17906695pubmed:meshHeadingpubmed-meshheading:17906695...lld:pubmed
pubmed-article:17906695pubmed:meshHeadingpubmed-meshheading:17906695...lld:pubmed
pubmed-article:17906695pubmed:meshHeadingpubmed-meshheading:17906695...lld:pubmed
pubmed-article:17906695pubmed:meshHeadingpubmed-meshheading:17906695...lld:pubmed
pubmed-article:17906695pubmed:meshHeadingpubmed-meshheading:17906695...lld:pubmed
pubmed-article:17906695pubmed:meshHeadingpubmed-meshheading:17906695...lld:pubmed
pubmed-article:17906695pubmed:meshHeadingpubmed-meshheading:17906695...lld:pubmed
pubmed-article:17906695pubmed:meshHeadingpubmed-meshheading:17906695...lld:pubmed
pubmed-article:17906695pubmed:meshHeadingpubmed-meshheading:17906695...lld:pubmed
pubmed-article:17906695pubmed:meshHeadingpubmed-meshheading:17906695...lld:pubmed
pubmed-article:17906695pubmed:meshHeadingpubmed-meshheading:17906695...lld:pubmed
pubmed-article:17906695pubmed:meshHeadingpubmed-meshheading:17906695...lld:pubmed
pubmed-article:17906695pubmed:meshHeadingpubmed-meshheading:17906695...lld:pubmed
pubmed-article:17906695pubmed:meshHeadingpubmed-meshheading:17906695...lld:pubmed
pubmed-article:17906695pubmed:meshHeadingpubmed-meshheading:17906695...lld:pubmed
pubmed-article:17906695pubmed:meshHeadingpubmed-meshheading:17906695...lld:pubmed
pubmed-article:17906695pubmed:meshHeadingpubmed-meshheading:17906695...lld:pubmed
pubmed-article:17906695pubmed:meshHeadingpubmed-meshheading:17906695...lld:pubmed
pubmed-article:17906695pubmed:meshHeadingpubmed-meshheading:17906695...lld:pubmed
pubmed-article:17906695pubmed:meshHeadingpubmed-meshheading:17906695...lld:pubmed
pubmed-article:17906695pubmed:meshHeadingpubmed-meshheading:17906695...lld:pubmed
pubmed-article:17906695pubmed:year2008lld:pubmed
pubmed-article:17906695pubmed:articleTitleCITED2 mediates the paradoxical responses of HIF-1alpha to proteasome inhibition.lld:pubmed
pubmed-article:17906695pubmed:affiliationDepartment of Pharmacology, Seoul National University College of Medicine, 28 Yongon-dong, Chongno-gu, Seoul, Korea.lld:pubmed
pubmed-article:17906695pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:17906695pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
entrez-gene:10370entrezgene:pubmedpubmed-article:17906695lld:entrezgene
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:17906695lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:17906695lld:pubmed